Search: (hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Klinisk medicin)) pers:(Ahrén Bo)
> (2010-2014) >
Effects of increasi...
Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice
- Article/chapterEnglish2011
Publisher, publication year, extent ...
-
American Physiological Society,2011
Numbers
-
LIBRIS-ID:oai:lup.lub.lu.se:a72fe7a2-1a9d-4d12-a154-28eff3a5d9b9
-
https://lup.lub.lu.se/record/1988169URI
-
https://doi.org/10.1152/ajpregu.00687.2010DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:art swepub-publicationtype
-
Subject category:ref swepub-contenttype
Notes
-
Chan HM, Jain R, Ahren B, Pacini G, D'Argenio DZ. Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice. Am J Physiol Regul Integr Comp Physiol 300: R1126-R1133, 2011. First published February 9, 2010; doi:10.1152/ajpregu.00687.2010.-The increase in insulin secretion caused by glucagon-like peptide-1 (GLP-1) and GLP-1 mimetics observed during an intravenous glucose test (IVGTT) has been reported in both normal and disease animal models, as well as in humans. In this study, a hierarchical population modeling approach is used, together with a previously reported model relating glucose to insulin appearance, to determine quantitative in vivo dose-response relationships between GLP-1 dose level and both first-and second-phase insulin release. Parameters of the insulin kinetic model were estimated from the complete set of glucose and insulin data collected in 219 anesthetized nonfasted NMR-imaged mice after intravenous injection of glucose (1 g/kg) alone or with GLP-1 (0.03-100 nmol/kg). The resulting dose-response curves indicate a difference in GLP-1 effect on the two release phases, as is also evident from the different ED50 parameter values (0.107 vs. 6.65 nmol/kg for phase 1 vs. phase 2 insulin release parameters). The first phase of insulin release is gradually augmented with increasing GLP-1 dose, reaching saturation at a dose of similar to 1 nmol/kg, while the second-phase release changes more abruptly at GLP-1 doses between 3 and 10 nmol/kg and shows a more pronounced 100-fold increase between control and the high GLP-1 dose of 100 nmol/kg Moreover, separate disposition indices calculated for phase 1 and 2 insulin release, show a different pattern of increase with increasing GLP-1 dose.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Jain, Ritesh
(author)
-
Ahrén, BoLund University,Lunds universitet,Medicin, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)med-bah
(author)
-
Pacini, Giovanni
(author)
-
D'Argenio, David Z.
(author)
-
Medicin, LundSektion II
(creator_code:org_t)
Related titles
-
In:American Journal of Physiology: Regulatory, Integrative and Comparative Physiology: American Physiological Society300:5, s. 1126-11330363-61191522-1490
Internet link
Find in a library
To the university's database